Oral abrocitinib ‘effective’ for teens with atopic dermatitis
Results from a phase 3 trial of the investigational JAK-1 selective inhibitor
The investigational drug oral abrocitinib, plus topical therapy, was safe and more effective than placebo with topical therapy in adolescents with moderate-to-severe atopic dermatitis (AD) according to clinical trial results.
The JADE TEEN phase 3 study of the Janus kinase (JAK)-1 selective inhibitor was conducted in the Asia-Pacific region, Europe and North America and included Australian patients.
